Quantitative PET coronary flow capacity and comprehensive management of chronic CAD: Lessons from the randomized

K Lance Gould1, Nils P Johson1

  • 1From the Weatherhead PET Center for Preventing and Reversing Atherosclerosis, Division of Cardiology, Department of Medicine, McGovern Medical School, University of Texas, and Memorial Hermann Hospital, Houston, TX, USA.

Atherosclerosis
|July 11, 2026
PubMed

Insights

A comprehensive strategy for chronic coronary artery disease (CAD) significantly reduced death, myocardial infarction (MI), and revascularization compared to standard care. This approach integrated lifestyle changes and medical treatment, reserving revascularization for severe cases identified by coronary flow capacity (CFC) testing.

Area of Science:

  • Cardiology and Cardiovascular Diseases
  • Preventive Medicine
  • Medical Interventions

Background:

  • Previous randomized trials in chronic coronary artery disease (CAD) focused on single interventions.
  • The CENTURY trial investigated a comprehensive strategy combining lifestyle modification, medical treatment, and revascularization.
  • Revascularization was reserved for patients with severely reduced coronary flow capacity (CFC) identified by positron emission tomography (PET).

Purpose of the Study:

  • To compare a comprehensive care strategy against standard community care for patients with high-risk CAD.
  • To evaluate the impact of the comprehensive strategy on reducing death, myocardial infarction (MI), and revascularization.
  • To assess the role of CFC quantification by PET in guiding revascularization decisions.

Main Methods:

  • 1028 high-risk CAD patients were randomized to either comprehensive or standard care.
  • Coronary flow capacity (CFC) was assessed using rest-stress PET at baseline, 2, and 5 years.
  • Comprehensive care involved frequent support and PET result review; standard care had limited contact and blinded PET results.

Main Results:

  • Comprehensive care significantly reduced summed risk factor score, all-cause death (4.7% vs. 8.2%), death or MI (7.0% vs. 11.1%), and revascularization (9.6% vs. 14.8%) at 5 years.
  • Major adverse cardiac events were significantly lower in the comprehensive care group (20.5% vs. 29.9%).
  • Intense adherence to comprehensive risk factor control correlated with further reductions in adverse events during extended follow-up.

Conclusions:

  • The CENTURY trial demonstrated that a comprehensive integrated approach significantly reduces mortality and major adverse cardiac events in chronic CAD patients.
  • Reserving revascularization for severely reduced CFC, guided by PET, proved effective and safe.
  • This strategy offers a promising model for managing chronic CAD, emphasizing prevention and tailored interventions.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...